Pacer Advisors Inc. Takes $6 Million Position in Becton Dickinson and Co (BDX)

Pacer Advisors Inc. acquired a new position in shares of Becton Dickinson and Co (NYSE:BDX) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 24,012 shares of the medical instruments supplier’s stock, valued at approximately $5,996,000.

Several other institutional investors also recently made changes to their positions in the company. Northwest Quadrant Wealth Management LLC boosted its stake in Becton Dickinson and by 5.2% in the 1st quarter. Northwest Quadrant Wealth Management LLC now owns 1,767 shares of the medical instruments supplier’s stock worth $444,000 after buying an additional 88 shares during the last quarter. Centric Wealth Management raised its position in shares of Becton Dickinson and by 6.6% during the 1st quarter. Centric Wealth Management now owns 3,832 shares of the medical instruments supplier’s stock valued at $957,000 after buying an additional 237 shares in the last quarter. Bank of The West raised its position in shares of Becton Dickinson and by 31.9% during the 1st quarter. Bank of The West now owns 12,125 shares of the medical instruments supplier’s stock valued at $3,028,000 after buying an additional 2,932 shares in the last quarter. Quad Cities Investment Group LLC raised its position in shares of Becton Dickinson and by 8.3% during the 1st quarter. Quad Cities Investment Group LLC now owns 1,415 shares of the medical instruments supplier’s stock valued at $351,000 after buying an additional 109 shares in the last quarter. Finally, Boyd Watterson Asset Management LLC OH purchased a new stake in shares of Becton Dickinson and during the 1st quarter valued at $357,000. 84.82% of the stock is owned by institutional investors and hedge funds.

In other Becton Dickinson and news, CEO Vincent A. Forlenza sold 11,340 shares of the stock in a transaction dated Monday, February 25th. The shares were sold at an average price of $250.40, for a total transaction of $2,839,536.00. Following the transaction, the chief executive officer now directly owns 227,250 shares in the company, valued at approximately $56,903,400. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Vincent A. Forlenza sold 3,123 shares of the firm’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $255.03, for a total transaction of $796,458.69. Following the completion of the sale, the chief executive officer now owns 215,372 shares in the company, valued at $54,926,321.16. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 29,684 shares of company stock worth $7,518,574. 0.12% of the stock is owned by company insiders.

Several research firms have recently weighed in on BDX. Zacks Investment Research upgraded shares of Becton Dickinson and from a “sell” rating to a “hold” rating in a research report on Wednesday. TheStreet upgraded shares of Becton Dickinson and from a “c+” rating to an “a” rating in a research report on Tuesday, February 5th. ValuEngine cut shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a research report on Monday, April 1st. Morgan Stanley lowered their price objective on shares of Becton Dickinson and from $265.00 to $240.00 and set an “equal weight” rating on the stock in a research report on Wednesday, January 2nd. Finally, Piper Jaffray Companies raised their price objective on shares of Becton Dickinson and to $274.00 and gave the company an “overweight” rating in a research report on Tuesday, February 5th. Six investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Becton Dickinson and currently has an average rating of “Buy” and an average price target of $255.75.

Shares of NYSE:BDX opened at $252.23 on Thursday. The firm has a market capitalization of $67.87 billion, a P/E ratio of 22.91, a price-to-earnings-growth ratio of 1.76 and a beta of 1.21. Becton Dickinson and Co has a 52 week low of $208.62 and a 52 week high of $265.87. The company has a debt-to-equity ratio of 0.83, a quick ratio of 0.62 and a current ratio of 0.97.

Becton Dickinson and (NYSE:BDX) last issued its earnings results on Tuesday, February 5th. The medical instruments supplier reported $2.70 EPS for the quarter, topping analysts’ consensus estimates of $2.58 by $0.12. Becton Dickinson and had a net margin of 5.69% and a return on equity of 14.65%. The company had revenue of $4.16 billion for the quarter, compared to analysts’ expectations of $4.10 billion. During the same quarter last year, the company earned $2.48 EPS. The firm’s revenue was up 35.1% compared to the same quarter last year. As a group, equities analysts forecast that Becton Dickinson and Co will post 12.09 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Friday, March 29th. Shareholders of record on Friday, March 8th were issued a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 1.22%. The ex-dividend date of this dividend was Thursday, March 7th. Becton Dickinson and’s payout ratio is 27.97%.

TRADEMARK VIOLATION WARNING: This news story was originally posted by WKRB News and is owned by of WKRB News. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international trademark and copyright law. The legal version of this news story can be accessed at https://www.wkrb13.com/2019/04/11/pacer-advisors-inc-takes-6-million-position-in-becton-dickinson-and-co-bdx.html.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Featured Story: How is a Moving Average Calculated?

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.